Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: DRUG: Capivasertib|DRUG: Fulvestrant|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib
Sponsor: AstraZeneca